Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Sales (2018 - 2024)

Denali Therapeutics (DNLI) has disclosed Return on Sales for 7 consecutive years, with 1.38% as the latest value for Q3 2024.

  • On a quarterly basis, Return on Sales rose 7704.0% to 1.38% in Q3 2024 year-over-year; TTM through Sep 2024 was 1.38%, a 162.0% increase, with the full-year FY2023 number at 0.44%, up 9550.0% from a year prior.
  • Return on Sales was 1.38% for Q3 2024 at Denali Therapeutics, down from 1.35% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 36.68% in Q2 2023 to a low of 4290.35% in Q4 2022.
  • A 5-year average of 374.69% and a median of 4.05% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -428433bps in 2022, then soared 428993bps in 2023.
  • Denali Therapeutics' Return on Sales stood at 13.13% in 2020, then skyrocketed by 54bps to 6.01% in 2021, then tumbled by -71238bps to 4290.35% in 2022, then skyrocketed by 100bps to 0.42% in 2023, then tumbled by -232bps to 1.38% in 2024.
  • Per Business Quant, the three most recent readings for DNLI's Return on Sales are 1.38% (Q3 2024), 1.35% (Q2 2024), and 0.46% (Q1 2024).